Analysts Slash Targets Higher on Networking, Biotech

Wall Street turned bullish today. Three notable upgrades stand out from the latest analyst activity.

ANET drew the biggest move. Rosenblatt's Mike Genovese lifted his price target to $280 from $210 — a 33% jump. He kept his Buy rating. The consensus target also nudged higher to $221. Arista Networks carries a $233 billion market cap with short interest at just 1.7% of free float.

ZBRA got a second look from Needham. James Ricchiuti raised his target to $410 from $345, a 19% increase. He maintained a Buy. Zebra Technologies is a $13.9 billion mid-cap in enterprise tech. Short interest sits at 7% of free float — moderate but worth watching.

BMO Capital's Evan Seigerman moved AMGN to Buy. His new target is $450, up from $400. Amgen is a $204 billion biotech giant. Short sellers show little concern, with SI at just 2.4% of free float.

On the downside, Barclays cut FIS to Hold. Nik Cremo trimmed his target to $43 from $44. Fidelity National Information Services faces a divided analyst community — 15 Buys but 11 Holds.

BKNG also got a boost. BMO's Brian Pitz raised his target to $250 and reiterated Buy on the travel platform.